Presentation is loading. Please wait.

Presentation is loading. Please wait.

Liz Corteville, Medicines Optimisation

Similar presentations


Presentation on theme: "Liz Corteville, Medicines Optimisation"— Presentation transcript:

1 Saving Lives from AF-related Stroke in West Hampshire CCG Optimising oral anticoagulation in AF
Liz Corteville, Medicines Optimisation Cardiovascular Lead Pharmacist, West Hampshire CCG Primary Care Pharmacists Association – Symposium 17th January 2017

2 Atrial fibrillation Very common in the elderly On the increase
AF can lead to life-threatening health problems Especially, stroke Stroke prevention is with OAC Reduce risk of stroke by 70% Aspirin /antiplatelet monotherapy no longer indicated for stroke prevention in AF (NICE)

3 1/3 of patients with AF will have a stroke
Atrial fibrillation Patients with AF are 5-6 times more likely to suffer a stroke than patients who do not have AF. AF related strokes are more severe and are more likely to be fatal. 1/3 of patients with AF will have a stroke It’s crucial to identify patients with AF in the community (often asymptomatic).

4 2,000 undiagnosed AF 12,000 10,500 West Hampshire CCG 51 practices
546,000 population 106,000 over 65s 16,000 over 85s 119,000 under 20 12,000 people with AF Ageing population 10,500 AF high risk stroke

5 Optimising Care: The Plan
Identify undiagnosed AF using WatchBP tool Identify and treat people not treated with OAC Identify people on warfarin sub-optimally-controlled

6 Optimising Care: The Patient at the Centre
Saving lives for people and families Saving time and money for the NHS

7 Optimising Care: The Method
Audit tools identified patients at high risk of stroke Results to GPs & continuous feedback on improvement Education and training was delivered Medicines Optimisation Incentive Scheme identification, feedback, education = continuous health improvement

8 Optimising Care: Collaborative Approach
350 GPs and their teams Donald

9 Optimising Care: GRASP AF
Total number of expected strokes annually Number of high risk patients prescribed anti-platelets Sep 14 167 Mar 16 129 Sept 16 128 Sep 14 2510 Mar 16 1651 Sept 16 1493 Number of high risk patients taking OAC Sept 16 7987 Mar 16 7524 Sep 14 5916

10 Optimising Care: WPSAT
Average % of warfarin patients with a TTR less than 40% Average % of warfarin patients with a TTR over 65% Apr % Mar 16 8.4% Sept 16 7.7% Mar 16 67% Sept 16 67% Apr 15 59%

11 Optimising Care: The Results
19 new cases AF diagnosed WatchBP GRASP AF 39 expected strokes avoided 2071 more OAC

12 Optimising Care: The Results
3000 people poorly-controlled on warfarin reviewed WPSAT

13 Number of reported strokes across WHCCG

14 Optimising Care: Paying for Improvements
£1.7 million saved in 15/16 Mike Dr Chris Neil £1.5 million extra spent on DOACs for AF

15 Optimising Care: What next?
WatchBP to AliveCor Review 1500 high-risk patients receiving antiplatelet monotherapy Review 1500 high-risk patients not receiving OAC or those poorly-controlled on warfarin Getting improvement work embedded into routine clinical practice (including care home residents)

16 Optimising Care: DOACs and Frailty
DOACs have many advantages; fixed dosing, steady pharmacokinetics, lack of coagulation monitoring But compliance and adherence are crucial, as short half-life Falls risk often over-stated as reason for with-holding treatment Intracranial haemorrhage: DOACs better than warfarin in frequent fallers Low body weight common in frail elderly; caution dosing Overall, in elderly patients with polypharmacy DOACs fewer interactions than warfarin However, each DOAC has own set of drug interactions Applying to Care Home population

17 Optimising Care: Making DOACs safer
Carry out full risk-benefit analysis including medication review before commencement/ annually on continued use Review regularly (NICE – annually; EHRA 1/12 after initiation then every 3/12) Care with correct dosage (under- and over- dosage) and ordering frequency Use creatinine clearance to calculate renal function (not eGFR) – might need switch to warfarin Always check co-prescribing DOAC and antiplatelet agents are specialist approved Check for drug interactions Check no duplication of anticoagulant (switch protocol) Educate patients/carers/ home staff re what bleeding looks like

18 Optimising Care: Reporting Bleeds
Prolonged nosebleeds (over 10 minutes) Blood in vomit Blood in sputum Passing blood in urine or faeces Passing black faeces Severe (larger than palm of hand) or spontaneous bruising Unusual headaches In women heavy or increased menstrual/vaginal loss Involved in major trauma

19 Prioritising patients for review – Polypharmacy Prioritisation Tool

20 Prioritising patients for review – filter for e. g
Prioritising patients for review – filter for e.g. OAC, antiplatelets, digoxin and low eGFR

21 Optimising Care: Patient-centred
Getting OAC improvement work embedded into care homes Challenges are similar for residents as for general population frailty; safety; training (reporting bleeds); adherence To conclude I’m pleased to have been able to share with you A POWERFUL REPRODUCIBLE COLLABORATIVE Way of carrying out HEALTH IMPROVEMENT To the benefit of PATIENTS and the NHS


Download ppt "Liz Corteville, Medicines Optimisation"

Similar presentations


Ads by Google